Baker Bros. Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Baker Bros. Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-520,523	Closed	-$11.5M	–	122
2021 Q3	$11.5M	Sell	520,523 -599,439	-54%	-$9.51M	0.05%	76
2021 Q2	$14.5M	Sell	1,119,962 -290,102	-21%	-$3.7M	0.06%	69
2021 Q1	$18.3M	Hold	1,410,064	–	–	0.08%	62
2020 Q4	$19.5M	Sell	1,410,064 -207,965	-13%	-$3.03M	0.07%	57
2020 Q3	$23.8M	Sell	1,618,029 -83,900	-5%	-$1.22M	0.1%	48
2020 Q2	$27.7M	Hold	1,701,929	–	–	0.12%	42
2020 Q1	$24.7M	Hold	1,701,929	–	–	0.15%	36
2019 Q4	$34.5M	Buy	+1,701,929	New	+$15.7M	0.18%	36
2016 Q3	–	Sell	-711,499	Closed	-$2.12M	–	135
2016 Q2	$2.12M	Hold	711,499	–	–	0.02%	97
2016 Q1	$2.08M	Hold	711,499	–	–	0.02%	99
2015 Q4	$1.79M	Hold	711,499	–	–	0.01%	110
2015 Q3	$2M	Hold	711,499	–	–	0.02%	103
2015 Q2	$2.13M	Hold	711,499	–	–	0.02%	101
2015 Q1	$3.12M	Sell	711,499 -16,170	-2%	-$64.1K	0.03%	93
2014 Q4	$2.6M	Hold	727,669	–	–	0.03%	95
2014 Q3	$2.34M	Buy	+727,669	New	+$2.59M	0.03%	86

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

MAM

Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Baker Bros. Advisors's AUPH Position: Q4 2021 in Review

Baker Bros. Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2021, closing a stake of 520,523 shares — an estimated $11.5M sold.

Baker Bros. Advisors first reported a position in AUPH in Q3 2014 and held it in 16 quarters. The position peaked at $34.5M in Q4 2019. 190 funds tracked by Wall St. Rank hold AUPH as of Q4 2021.

Baker Bros. Advisors reported no remaining Aurinia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Baker Bros. Advisors sold 520,523 Aurinia Pharmaceuticals shares in Q4 2021, an estimated $11.5M.
Baker Bros. Advisors first reported a position in Aurinia Pharmaceuticals in Q3 2014 and held it in 16 quarters.
Baker Bros. Advisors's Aurinia Pharmaceuticals position peaked at $34.5M in Q4 2019.
190 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2021.

Based on Baker Bros. Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.